Zomedica
Zomedica is a publicly traded animal health company that develops and sells diagnostic platforms (TRUFORMA, TRUVIEW, VETGuardian PLUS) and therapeutic devices (Assisi tPEMF, PulseVet shock wave, VETIGEL) to companion animal and equine veterinarians across the US, Canada, and the EU via direct sales and distribution partners.
- Company typePublic
- Founded2016
- HeadquartersAnn Arbor, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Zomedica does
Zomedica is a publicly traded animal health company (NYSE American: ZOM; OTCQB: ZOMDF) headquartered in Ann Arbor, Michigan, that develops and sells diagnostic and therapeutic products for companion animal and equine veterinarians in the United States, Canada, and the European Union. Its portfolio spans four sub-brands: ZOM•Dx diagnostic platforms (TRUFORMA biosensor testing, TRUVIEW automated digital microscopy with AI-driven cytology interpretation, VETGuardian PLUS zero-touch vital signs monitoring, and SonoView); Assisi tPEMF therapy products (Loop, Loop Lounge, DentaLOOP, Calmer Canine) for drug-free pain management; PulseVet shock wave therapy systems for regenerative equine and small-animal treatment; and VETIGEL plant-based hemostatic gel for surgical bleeding control.
The company generates revenue primarily through hardware sales of its diagnostic and therapeutic devices, paired with a recurring consumables model on TRUFORMA analyzer placements and a contract manufacturing arrangement (Rahm Sensor Development/Cell-Guardian) that leverages its Roswell, Georgia and Plymouth, Minnesota manufacturing facilities. Zomedica goes to market through a direct US sales force targeting companion animal and equine clinics, supplemented by channel partnerships — Moichor for US TRUVIEW distribution, Grovet b.v. for the EU, UXR for Canada, and Boehringer Ingelheim Animal Health for equine PPID diagnostic testing under a reimbursement program.
Zomedica built its portfolio primarily through acquisition, including Pulse Veterinary Technologies (2021, $70.9 million), Revo Squared (2022), Assisi Animal Health (2022), Structured Monitoring Products/PIMS (2023), and Qorvo Biotech (2023). The company reported $32.0 million in full-year 2025 revenue (17% year-over-year growth) and $8.8 million in Q1 2026 revenue (35% year-over-year growth), marking 21 consecutive quarters of record year-over-year revenue, with 68% gross margins in 2025 and approximately $48 million in liquidity as of March 31, 2026.
Zomedica firmographics
Firmographics- Name
- Zomedica
- Legal name
- Zomedica Inc.
- Website
- https://zomedica.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Zomedica is a publicly traded animal health company that develops and sells diagnostic platforms (TRUFORMA, TRUVIEW, VETGuardian PLUS) and therapeutic devices (Assisi tPEMF, PulseVet shock wave, VETIGEL) to companion animal and equine veterinarians across the US, Canada, and the EU via direct sales and distribution partners.
- Ownership category
- akta.pro rank
Zomedica industry classification
Industry- Product category
- Veterinary Diagnostics and Therapeutics
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Veterinary Services (541940)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Companion Animal Therapeutics (Rx) (HLAMAEAA)
- akta.pro secondary industries
- Equine Therapeutics (Rx) (HLAMAEAC), Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF)
Keywords
Where Zomedica is headquartered
LocationHeadquarters
- HQ city
- Ann Arbor
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Zomedica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain
Revenue model
- Diagnostic Equipment and Consumables: Point-of-care diagnostic equipment (TRUFORMA, TRUVIEW, VETGuardian) sold alongside recurring consumable revenue through analyzer and cartridge system. Each system placement generates recurring consumables revenue.
- Therapeutic Devices: Sale of therapeutic devices including PulseVet shock wave system, Assisi tPEMF products (LOOP, Loop Lounge, DentaLOOP, Calmer Canine), and VETIGEL hemostatic gel.
- Contract Manufacturing Services: Leverages existing manufacturing infrastructure to generate contract-based revenue beyond core animal health business through OEM manufacturing partnerships (Rahm sensor manufacturing deal for Cell-Guardian).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Hybrid | Pay-as-you-go | Diagnostic platforms with recurring consumables |
Go-to-market motion5 records
Distribution channels5 records
Marketing channels6 records
Zomedica product offering
Product offeringCore offering
Zomedica develops, manufactures, and sells diagnostic and therapeutic medical devices for veterinary clinics treating companion animals (dogs, cats) and equine patients. Its product portfolio includes point-of-care biosensor diagnostic platforms (TRUFORMA), automated digital cytology microscopes (TRUVIEW), zero-touch patient vital signs monitors (VETGuardian PLUS), targeted pulsed electromagnetic field therapy devices (Assisi LOOP line), shock wave therapy systems (PulseVet), and hemostatic gels (VETIGEL). Revenue is generated through instrument placements combined with recurring consumable cartridge sales, alongside therapeutic device sales.
Product overview
Zomedica is an animal health company offering an integrated portfolio of diagnostic and therapeutic products for equine and companion animals. The product portfolio consists of multiple distinct platforms and product lines: (1) ZOM-Dx diagnostic division including TRUFORMA (point-of-care biosensor testing platform), TRUVIEW (fully automated digital microscopy with AI), VETGuardian PLUS (zero-touch vital signs monitoring), and SonoView; (2) Assisi tPEMF therapy line including Assisi LOOP, Loop Lounge, DentaLOOP, and Calmer Canine for drug-free pain management; (3) PulseVet shock wave therapy systems including the PulseVet device, X-Trode, and Equine Trode Set for regeneration; and (4) VETIGEL hemostatic gel for bleeding control. The company operates a consumables/revenue model alongside device placements, with products serving both companion animal and equine veterinary markets.
Differentiator
Problem solved
Functional benefit
Brands
- ZOM•Dx: Diagnostic products including TRUFORMA, TRUVIEW, VETGuardian PLUS, and SonoView platforms for veterinary diagnostics
- Assisi
- PulseVet
- VETIGEL
Products and services
- TRUFORMA In-clinic biosensor testing platform that enables point-of-care diagnostic testing with rapid results for veterinary applications including endocrine testing (ACTH for PPID diagnosis, progesterone for reproductive health), cardiac biomarkers (NT-proBNP), and other diagnostic assays. Sold to veterinary clinics with recurring cartridge-based consumables revenue.
- TRUVIEW The only fully automated digital microscope that prepares and digitizes hematology and cytology slides for review in minutes. Includes AI-powered diagnostic interpretation for automated analysis of hematology blood films with skin and ear cytology support.
- VETGuardian PLUS Zero-touch vital signs remote monitor that ensures pets are safe and supervised from intake to discharge, featuring non-contact monitoring, live video with night vision, and thermal imaging capabilities for veterinary clinics.
- SonoView Diagnostic platform that is part of ZOM-Dx portfolio for veterinary ultrasound or imaging diagnostics.
- Assisi LOOP Portable, versatile, drug-free tPEMF therapy device clinically proven to decrease pain and inflammation in pets. Part of Assisi's targeted pulsed electromagnetic field therapy product line for veterinary use.
- Loop Lounge Rechargeable therapy pad offering total body drug-free relief from pain and inflammation for cats and dogs of all sizes using tPEMF technology.
- DentaLOOP Specialized tPEMF therapy device engineered for treating dental and oral pain in pets, applying proven Assisi LOOP technology in a design specifically for oral applications.
- Calmer Canine Drug-free targeted PEMF therapy device clinically proven to offer long-term relief from canine separation anxiety.
- PulseVet Shock Wave System Leading veterinary shock wave therapy device for regeneration, featuring swivel screen, Bluetooth operation, and preset treatment parameters. Backed by over 20 years of clinical research supporting shock wave therapy effectiveness.
- VETIGEL Hemostatic Gel Plant-based hemostatic gel that stops bleeding in less than ten seconds, potentially reducing blood loss, anesthesia time, and improving patient outcomes. Supplied in pre-filled syringes ready for immediate use in veterinary surgery.
Quantifiable outcome
- 68% gross margin achieved in 2025
- +4 more outcomes
Companies that use Zomedica
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Zomedica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature7 records
Zomedica partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- Fear Free, LLCminorRenewed alliance with Fear Free, LLC to continue promoting low-stress veterinary care and pet wellbeing through Assisi Loop tPEMF therapy products. Partnership focuses on educating veterinary professionals on stress-reducing protocols and expanding awareness of non-invasive treatment options.
- United States Eventing Association (USEA)minorRenewed sponsorship agreement maintaining PulseVet's designation as the 'Official Shock Wave of the USEA' for another year. Partnership supports USEA programs focused on educating and celebrating riders, owners, trainers, and veterinarians within the sport of Eventing.
- Boehringer Ingelheim Animal Health USA Inc.coreStrategic collaboration to integrate Zomedica's TRUFORMA diagnostic platform into Boehringer Ingelheim's idPPID awareness and testing program for pituitary pars intermedia dysfunction in horses. Boehringer will reimburse participating veterinarians for diagnostic testing, expand Zomedica's installed base, and drive recurring cartridge revenue. PPID affects approximately 20-25% of horses over 15 years of age.
- Boehringer Ingelheim Animal HealthcoreCollaboration where Boehringer Ingelheim will reimburse veterinarians for diagnostic testing performed with Zomedica's TRUFORMA platform and provide no-cost analyzer placements in equine veterinary practices, accelerating TRUFORMA adoption.
- MoichorcoreCommercial distribution agreement with Moichor, a veterinary pathology services provider, for TRUVIEW digital microscopy platform. Co-branded systems integrate Moichor's proprietary AI engine and board-certified pathology services for point-of-care veterinary customers nationwide, spanning companion animal and exotic animal practices.
- Rahm Sensor DevelopmentminorContract manufacturing and services agreement to manufacture Cell-Guardian, a personnel monitoring device for high-risk environments such as correctional settings. Zomedica leverages existing manufacturing infrastructure to generate contract-based revenue and improve asset utilization.
- Grovet b.v.coreExpanded distribution agreement with Grovet b.v. to include Zomedica's diagnostic and therapeutic device products across the European Union, strengthening Zomedica's presence in the European veterinary market.
- UXRcoreExpanded distribution agreement with UXR in Canada for Zomedica's diagnostic and therapeutic products, expanding market reach in the Canadian veterinary market.
Scale indicators12 records
Recent moves6 records
Expansion highlights6 records
Zomedica competitors and assessment
Company assessmentDirect peers
- IDEXX Laboratories: IDEXX is the dominant veterinary diagnostics company with reference lab services, in-clinic analyzers (Catalyst, ProCyte, SNAP), and a broad assay menu. It is the primary competitive benchmark for Zomedica's TRUFORMA and TRUVIEW platforms, both directly and via former Zomedica executives with IDEXX backgrounds.
- Antech Diagnostics (Mars Veterinary Health): Antech is the largest veterinary reference laboratory in North America and offers in-clinic diagnostics, imaging, and teleconsultation. Several Zomedica leaders (Paul Tye, Adrienne Bricaud) previously held senior roles at Antech, underscoring the direct competitive and customer overlap with Zomedica's diagnostic offerings.
- Heska (now part of Mars Petcare): Heska specialized in veterinary in-clinic diagnostics (chemistry, hematology, immunoassay) and point-of-care testing before being acquired by Mars Petcare. It is a direct competitor to Zomedica's TRUFORMA platform and shares target customers (US companion animal clinics).
- Covetrus: Covetrus is a leading distributor of veterinary products, services, and technologies, including in-clinic diagnostic platforms. Comparable to Zomedica on the distribution side of the veterinary diagnostic value chain and a potential channel partner or competitive threat to direct sales.
Broad incumbents
- Zoetis: Zoetis is the world's largest animal health company with diagnostics, devices, pharmaceuticals, and vaccines across companion and livestock animals. Zomedica's VP of Corporate & Strategic Partnerships came from Zoetis, and Zoetis represents both a competitor (in therapeutic devices and diagnostics) and a potential strategic acquirer.
- Elanco Animal Health: Elanco is a major global animal health company offering companion animal and livestock therapeutics, vaccines, and diagnostics. It is a broad incumbent comparable to Zomedica's therapeutic device and diagnostic portfolio, with substantially greater scale and distribution reach.
- Dechra Pharmaceuticals: Dechra (acquired by EQT) is a specialty veterinary pharmaceuticals company focused on companion animal endocrinology, dermatology, and pain management. Its pain-management focus is comparable to Zomedica's Assisi tPEMF and PulseVet therapeutic franchises.
- Virbac: Virbac is a global animal health company providing pharmaceuticals, vaccines, and diagnostics for companion and production animals. Comparable to Zomedica's equine and companion animal therapeutic portfolio, though with a much broader product range and geographic footprint.
- Vetoquinol: Vetoquinol is a French veterinary pharmaceutical company specializing in companion animal therapeutics with growing presence in the US. Comparable to Zomedica on equine and companion animal therapeutic devices, though primarily a pharmaceutical rather than device company.
Emerging players
- PetIQ: PetIQ is a US pet health and wellness company offering veterinary products, OTC supplements, and clinic services. While focused on different categories (preventives and wellness), it overlaps with Zomedica on the broader US companion animal health opportunity and similar end-customer base of pet owners and vets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Zomedica social profiles
Digital presenceZomedica compliance and trust
Trust signalCompliance5 records
Zomedica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Zomedica leadership team
Management profileNumber of profiles
Profiles19 records
Zomedica subsidiaries and ownership
Company hierarchySubsidiaries5 records
Zomedica funding detail
Funding detailFunding overview
Funding rounds8 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Zomedica M&A and investment
M&A and investmentM&A5 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Zomedica
What does Zomedica do?
Zomedica develops, manufactures, and sells diagnostic and therapeutic medical devices for veterinary clinics treating companion animals (dogs, cats) and equine patients. Its product portfolio includes point-of-care biosensor diagnostic platforms (TRUFORMA), automated digital cytology microscopes (TRUVIEW), zero-touch patient vital signs monitors (VETGuardian PLUS), targeted pulsed electromagnetic field therapy devices (Assisi LOOP line), shock wave therapy systems (PulseVet), and hemostatic gels (VETIGEL). Revenue is generated through instrument placements combined with recurring consumable cartridge sales, alongside therapeutic device sales.
Is Zomedica a public or private company?
Zomedica is a public company. It is classified as public and is currently operating.
When was Zomedica founded?
Zomedica was founded in 2016. It employs 101 to 250 people.
Where is Zomedica based?
Zomedica is headquartered in Ann Arbor, United States, in the North America region.
How does Zomedica make money?
Three revenue lines are on record. Diagnostic Equipment and Consumables are the primary driver. The others are therapeutic Devices and contract Manufacturing Services.
Who are Zomedica's main competitors?
Direct peers on record are IDEXX Laboratories, Antech Diagnostics (Mars Veterinary Health), Heska (now part of Mars Petcare) and Covetrus. Broad incumbents are Zoetis, Elanco Animal Health, Dechra Pharmaceuticals, Virbac and Vetoquinol. PetIQ is listed as an emerging player.
Does Zomedica have an API?
No public API is recorded for Zomedica.
What industry is Zomedica in?
Zomedica's product category is Veterinary Diagnostics and Therapeutics. Its primary akta.pro industry code is HLAMAEAA, Companion Animal Therapeutics (Rx), with a secondary code of HLAMAEAC, Equine Therapeutics (Rx). Its NAICS code is 3391 and its SIC code is 3841.